FDA gives priority review to Spectrum blood-cancer drug

The FDA has given a priority review designation to Spectrum Pharmaceuticals' (SPPI +3.5%) filing of a New Drug Application (NDA) for its Beleodaq blood-cancer treatment .

The FDA has set a deadline of August 9 for deciding whether or not to authorize Beleodaq.

Spectrum has requested that the FDA approve Beleodaq for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs